Triple Giving November OMF logo

 TRIPLE YOUR IMPACT during Triple Giving November | All Donations to OMF are TRIPLED through December 3

Search
Close this search box.

AusME Biobank Biomarker project

Study Aim

The study will utilise the Australian ME/CFS biobank for metabolomics analyses and other assays to identify potential biomarkers for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, contributing to a comprehensive dataset for large-scale analysis.

Investigators

  • Sarah Annesley, PhD
  • Paul Fisher, PhD
  • Brett Lidbury, PhD
  • Alice Richardson, PhD
  • Benjamin Heng, PhD
  • Elisha Josev, PhD
  • Paul Gooley, PhD
  • Christopher Armstrong, PhD

Updates and Potential

  • Data collection occurring in 2024.
  • Paper submission expected in 2025.
STUDY HYPOTHESIS AND DESCRIPTION

To enhance the research capabilities within the Australian scientific community concerning Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Long COVID, we played a role in establishing an Australian biobank for ME/CFS managed by Emerge Australia. The establishment of this biobank and registry included conducting a biomarker study utilising patient samples. Although the progress of the biobank was hindered by the pandemic, we have now successfully collected hundreds of samples from willing participants over the past few years.

As part of this initiative, we are currently performing metabolomics analyses on all samples stored in the biobank. This metabolomics data will be integrated with findings from other assays conducted by our collaborators. We plan to disseminate research papers detailing individual projects and subsequently compile a comprehensive dataset for large-scale analysis aimed at identifying potential biomarkers.

OBJECTIVES

close-up of a gloved hand holding a test tube containing a blood sample. The test tube is labeled with barcode for identification and tracking purposes.

  1. Pattern metabolites corresponding to patient symptoms and co-morbid conditions.
  2. Validate markers from previous studies.
  3. Search for new potential markers in this large Australian dataset.
  4. Cluster patients based on similar biology-symptom.
  5. Combine data with collaborator assays on same patients.
Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.


How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669